This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018. Steven Schwartz, M.D., is an ophthalmologist whose primary research areas include early diagnosis and treatment of diseases such as macular degeneration, retinopathy of prematurity and diabetic eye disease. Phase 2 controlled trials are planned with designs informed by these Phase 1 results. The hESC-RPE cell transplants, at all doses, seem safe and well tolerated for at least 3 years post-transplantation. BCVA, monitored as an uncontrolled safety parameter, was observed to substantially improve at years 1 and 2 in the majority of patients however, by 3-years post-transplantation, these improvements diminished. Patches of increasing subretinal hyperpigmentation, many consistent with RPE (imaged by OCT and AF), were observed near the transplant site in 92% (n=24/26) of patients. No dose-limiting toxicities were observed. At 3 years, no evidence of unanticipated persistent inflammation, hyperproliferation, tumor, ectopic (non-RPE) tissue, or serious stem-cell related adverse safety issues were observed. UCLA Health retina disease specialists treat a range of conditions, such as diabetic retinopathy, macular degeneration and retinal detachment. Of the 26 transplanted patients, 24 (n=11 AMD, median age 77 years n=13 SMD, median age 48 years ) reached a minimum follow-up of 36 months (range: 38–75) two AMD patients did not consent to participate in the long-term, follow-up study. Call 31 to request an appointment with a retina disease specialist at UCLA Health. Systemic and ocular outcomes were assessed by extensive examination, imaging, and laboratory studies. Patients received systemic immunosuppression for at least 13 weeks, starting 1 week prior to surgery. ![]() Patients had advanced degeneration in study eye (best-corrected visual acuity ≤20/400) a cohort of three patients with better vision (≤20/100 in the study eye) was later added to both trials. Multicenter, prospective, dose-escalating studies were carried out to determine the safety and tolerability of subretinal transplantation of hESC-RPE cells (50,000–200,000) in 13 patients with SMD and 13 with atrophic AMD. We present the first long-term (exceeding 3 years) safety and tolerability data from the transplantation of human embryonic stem cell-derived retinal pigment epithelial (hESC-RPE) cells into patients with Stargardt macular dystrophy (SMD) and atrophic age-related macular degeneration (AMD). You can find other locations and directions on Healthgrades. Schwartzs office is located at 100 Ucla Medical Plz, Los Angeles, CA 90024. He graduated from Tulane University School of Medicine in 1972. Additionally, his focus includes development and evaluation of novel medical device technologies, imaging technologies, surgical equipment (including surgical robots), and drug delivery systems.Pluripotent stem cells have the capacity for unlimited self-renewal and are a potential source of therapeutic material for regenerative medicine. Stephen Schwartz, MD is an orthopedic surgery specialist in Los Angeles, CA and has over 50 years of experience in the medical field. Schwartz’s primary research areas include early diagnosis and treatment of diseases such as macular degeneration, retinopathy of prematurity (ROP), and diabetic eye disease. ![]() He received his medical degree from the University of Southern California (USC) School of Medicine, completed an Internship at the USC Hospital in Medicine, Surgery and Anesthesia, a Residency in Ophthalmology at UCLA School of Medicine-Jules Stein Eye Institute, and a Fellowship in Retina/Uveitis at the UCL Institute of Ophthalmology, Moorfields Eye Hospital. ![]() Steven Schwartz currently serves as Ahmanson Professor of Ophthalmology, Professor-in-Residence of Ophthalmology, Chief of Retina Division, Director for Diabetic Eye Disease and Retinal Vascular Center, and Director of the Ophthalmic Photography Clinical Laboratory for Jules Stein Eye Institute at the University of California, Los Angeles (UCLA).
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |